摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-(3-fluoro-4-formyl-phenyl)-acrylic acid | 882506-67-4

中文名称
——
中文别名
——
英文名称
3-(3-fluoro-4-formyl-phenyl)-acrylic acid
英文别名
3-(3-Fluoro-4-formyl-phenyl)-acrylic acid;3-(3-fluoro-4-formylphenyl)prop-2-enoic acid
3-(3-fluoro-4-formyl-phenyl)-acrylic acid化学式
CAS
882506-67-4
化学式
C10H7FO3
mdl
——
分子量
194.162
InChiKey
HMPJGTIRORLMOD-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.4
  • 重原子数:
    14
  • 可旋转键数:
    3
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    54.4
  • 氢给体数:
    1
  • 氢受体数:
    4

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    3-(3-fluoro-4-formyl-phenyl)-acrylic acid苯乙酮氢氧化钾盐酸 作用下, 以 乙醇 为溶剂, 以73%的产率得到3-[3-fluoro-4-(3-oxo-3-phenyl-propenyl)-phenyl]-acrylic acid
    参考文献:
    名称:
    [EN] NEW HISTONE DEACETYLASES INHIBITORS
    [FR] NOUVEAUX INHIBITEURS DES HISTONE-DEACETYLASES
    摘要:
    新的组织脱乙酰化酶抑制剂具有抗肿瘤活性,以及其制备方法在此进行描述。这些化合物属于结构式(I),其中R1是含有至少两个共轭双键的直链或支链,A是可选择地取代的苯或吡啶环,Ar是芳基或杂芳基团,R3是氢或烷氧基烷基。该申请还描述了这些化合物在治疗与组织脱乙酰化酶活性失调相关的疾病,如肿瘤中的应用,以及用于给需要该治疗的患者的相关药物组合物。
    公开号:
    WO2006037761A1
  • 作为产物:
    描述:
    3-(3-fluoro-4-formyl-phenyl)-acrylic acid tert-butyl ester二氯甲烷三氟乙酸 为溶剂, 反应 6.0h, 以giving 1.62 g of 3-(3-fluoro-4-formyl-phenyl)-acrylic acid的产率得到3-(3-fluoro-4-formyl-phenyl)-acrylic acid
    参考文献:
    名称:
    Histone deacetylases inhibitors
    摘要:
    本文介绍了新型组蛋白去乙酰化酶抑制剂及其具有抗肿瘤活性的制备过程。这些化合物属于结构式(I),其中R1是一个含有至少两个共轭双键的线性或支链,A是一个可选取代的苯基或吡啶基环,Ar是芳基或杂环基团,R3是氢或烷氧基烷基。该申请还描述了使用这些化合物治疗与组蛋白去乙酰化酶活性失调相关的疾病,如肿瘤,以及适用于需要该治疗的患者的相关药物组合物。
    公开号:
    US08058273B2
点击查看最新优质反应信息

文献信息

  • Histone Deacetylases Inhibitors
    申请人:Minucci Saverio
    公开号:US20080096889A1
    公开(公告)日:2008-04-24
    New inhibitors of histone deacetylases having antitumor activity, and the process of preparation thereof are herein described. These compounds belong to the structural formula (I) where R 1 is a linear or branched chain containing at least two conjugated double bonds, A is an optionally substituted phenyl or pyridyl ring, Ar is an aryl or heteroaryl group, and R 3 is hydrogen or alkoxyalkyl. The application also describes the use of said compounds in the treatment of diseases associated to the deregulation of histone deacetylases activity, such as tumors, as well as the relevant pharmaceutical compositions for administration to patients requiring said treatment.
    本文描述了具有抗肿瘤活性的组蛋白去乙酰化酶新抑制剂及其制备过程。这些化合物属于结构式(I),其中R1是一个含有至少两个共轭双键的线性或支链,A是一个可选取代的苯基或吡啶基环,Ar是芳基或杂环基团,而R3是氢或烷氧基烷基。该申请还描述了这些化合物在治疗与组蛋白去乙酰化酶活性失调相关的疾病,如肿瘤方面的应用,以及用于给需要该治疗的患者的相关药物组成部分。
  • NEW HISTONE DEACETYLASES INHIBITORS
    申请人:MINUCCI Saverio
    公开号:US20100240660A1
    公开(公告)日:2010-09-23
    New inhibitors of histone deacetylases having antitumor activity, and the process of preparation thereof are herein described. These compounds belong to the structural formula (I) where R 1 is a linear or branched chain containing at least two conjugated double bonds, A is an optionally substituted phenyl or pyridyl ring, Ar is an aryl or heteroaryl group, and R 3 is hydrogen or alkoxyalkyl. The application also describes the use of said compounds in the treatment of diseases associated to the deregulation of histone deacetylases activity, such as tumors, as well as the relevant pharmaceutical compositions for administration to patients requiring said treatment.
    本文描述了具有抗肿瘤活性的新型组蛋白去乙酰化酶抑制剂及其制备方法。这些化合物属于结构式(I),其中R1是含有至少两个共轭双键的线性或支链,A是可选取代的苯基或吡啶基环,Ar是芳基或杂环芳基基团,R3是氢或烷氧基烷基。该申请还描述了在治疗与组蛋白去乙酰化酶活性失调相关的疾病,如肿瘤方面使用这些化合物的方法,以及适用于需要该治疗的患者的相关药物组合物。
  • [EN] NEW HISTONE DEACETYLASES INHIBITORS<br/>[FR] NOUVEAUX INHIBITEURS DES HISTONE-DEACETYLASES
    申请人:DAC SRL
    公开号:WO2006037761A1
    公开(公告)日:2006-04-13
    New inhibitors of histone deacetylases having antitumor activity, and the process of preparation thereof are herein described. These compounds belong to the structural formula (I) where R1 is a linear or branched chain containing at least two conjugated double bonds, A is an optionally substituted phenyl or pyridyl ring, Ar is an aryl or heteroaryl group, and R3 is hydrogen or alkoxyalkyl. The application also describes the use of said compounds in the treatment of diseases associated to the deregulation of histone deacetylases activity, such as tumors, as well as the relevant pharmaceutical compositions for administration to patients requiring said treatment.
    新的组织脱乙酰化酶抑制剂具有抗肿瘤活性,以及其制备方法在此进行描述。这些化合物属于结构式(I),其中R1是含有至少两个共轭双键的直链或支链,A是可选择地取代的苯或吡啶环,Ar是芳基或杂芳基团,R3是氢或烷氧基烷基。该申请还描述了这些化合物在治疗与组织脱乙酰化酶活性失调相关的疾病,如肿瘤中的应用,以及用于给需要该治疗的患者的相关药物组合物。
  • Histone deacetylases inhibitors
    申请人:DAC S.R.L.
    公开号:US08058273B2
    公开(公告)日:2011-11-15
    New inhibitors of histone deacetylases having antitumor activity, and the process of preparation thereof are herein described. These compounds belong to the structural formula (I) where R1 is a linear or branched chain containing at least two conjugated double bonds, A is an optionally substituted phenyl or pyridyl ring, Ar is an aryl or heteroaryl group, and R3 is hydrogen or alkoxyalkyl. The application also describes the use of said compounds in the treatment of diseases associated to the deregulation of histone deacetylases activity, such as tumors, as well as the relevant pharmaceutical compositions for administration to patients requiring said treatment.
    本文介绍了新型组蛋白去乙酰化酶抑制剂及其具有抗肿瘤活性的制备过程。这些化合物属于结构式(I),其中R1是一个含有至少两个共轭双键的线性或支链,A是一个可选取代的苯基或吡啶基环,Ar是芳基或杂环基团,R3是氢或烷氧基烷基。该申请还描述了使用这些化合物治疗与组蛋白去乙酰化酶活性失调相关的疾病,如肿瘤,以及适用于需要该治疗的患者的相关药物组合物。
查看更多